DB18520InvestigationalGene Therapies
HMI-203 is an investigational gene therapy developed by Homology Medicines, Inc. It consists of a recombinant adeno-associated virus (AAV) serotype HSC15 (rAAVHSC15) encoding human iduronate-2-sulfatase (hIDS).
- Code names
- HMI-203
What you can answer from here — as of April 23, 2025
Which companies are running trials of HMI-203, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account